Axogen Inc (NASDAQ: AXGN) kicked off on Monday, down -5.85% from the previous trading day, before settling in for the closing price of $33.51. Over the past 52 weeks, AXGN has traded in a range of $9.22-$34.71.
A company in the Healthcare sector has jumped its sales by 21.24% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 123.78%. With a float of $45.17 million, this company’s outstanding shares have now reached $46.12 million.
Axogen Inc (AXGN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Axogen Inc is 2.07%, while institutional ownership is 90.65%. The most recent insider transaction that took place on Dec 16 ’25, was worth 1,280,465. In this transaction Director of this company sold 43,684 shares at a rate of $29.31, taking the stock ownership to the 93,826 shares. Before that another transaction happened on Dec 16 ’25, when Company’s Director sold 46,653 for $29.55, making the entire transaction worth $1,378,476. This insider now owns 0 shares in total.
Axogen Inc (AXGN) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.07 earnings per share (EPS), higher than consensus estimate (set at 0.04) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 123.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 80.96% during the next five years compared to 21.24% growth over the previous five years of trading.
Axogen Inc (NASDAQ: AXGN) Trading Performance Indicators
Take a look at Axogen Inc’s (AXGN) current performance indicators. Last quarter, stock had a quick ratio of 2.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.78. Likewise, its price to free cash flow for the trailing twelve months is 435.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.05, a number that is poised to hit 0.06 in the next quarter and is forecasted to reach 0.49 in one year’s time.
